Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Calcium fructoborate effect on systemic inflammation and dyslipidaemia markers in middle-aged people with primary osteoarthritis
ISRCTN ISRCTN46679573
ClinicalTrials.gov identifier
Public title Calcium fructoborate effect on systemic inflammation and dyslipidaemia markers in middle-aged people with primary osteoarthritis
Scientific title A double-blind, placebo-controlled pilot study to evaluate FruitexB® (calcium fructoborate) effect on systemic inflammation and dyslipidaemia markers in middle-aged people with primary osteoarthritis
Acronym FruiteB
Serial number at source Research Project no.12/2008
Study hypothesis The safe and efficacious use of the FruitexB® (chemical natural-identical plant based dietary boron) in other inflammatory diseases prompted us to do this study of its anti-inflammatory effects in patients with osteoarthritis (OA) symptoms. The main objective of this approach was to evaluate whether or not FruitexB®, in a double-blind, placebo-controlled, randomly allocated trial with patients suffering from knee osteoarthritis symptoms, may cause any statistically significant favourable effect on systemic inflammation and dyslipidemia markers when compared with the placebo group.
Lay summary
Ethics approval Institutional Ethics Committee of the University of Medicine and Pharmacy of Craiova, Romania, approved in March 2008 (ref: 364/2008). The trial is also in compliance with the Helsinki Declaration of 1975 as revised in 1983.
Study design Randomised double-blind placebo-controlled single centre trial
Countries of recruitment Romania
Disease/condition/study domain Primary osteoarthritis
Participants - inclusion criteria 1. Men and non-pregnant women
2. Aged 40 - 85 years
3. Primary OA of at least one knee as demonstrated by a radiological examination carried out within the previous 3 months
4. Body mass index (BMI) less than 28 and greater than 24.4 kg/m^2
5. Elevated blood levels of at least one inflammatory marker
Participants - exclusion criteria 1. Individuals with digestion problems
2. Subjects with a fever and/or under treatment with antibiotics
3. Subjects with fructose intolerance
4. Subjects taking any painkillers and/or vitamin B6
5. Subjects taking aspirin
6. Current use of non-steroidal anti-inflammatory drugs (NSAIDS) and acetominophen
Anticipated start date 10/03/2008
Anticipated end date 30/08/2009
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 60 patients
Interventions The study was double-blind and placebo-controlled. For ease of presentation the four subject groups are given the following descriptors:
Group 1: 30 mg FruitexB® twice per day
Group 2: 60 mg FruitexB® twice per day
Group 3: 120 mg FruitexB® twice per day
Group 4: 120 mg placebo twice per day. Placebo material was based on fructose only.

The duration of the treatment was 2 weeks, administered as 2 capsules twice per day (BID) ingested orally with meals. Survey on dietary intake was carried out by personal interview. Interviewers presented tableware and food models and investigated the meal intake on 2 different weekdays and 1 weekend day based on recall method. Nutrient intake was calculated by use of the DietSYS+Plus (version 5.9), dietary analysis program (Block Dietary Data Systems). The DietSYS+Plus database, a software that analyses nutrients, was expanded for the present study to include dietary boron values in foods consumed in Romania. After calculating the intake of nutrients per individual, percentage of the intake was calculated in relation to Dietary Reference Intakes for Romania. Subsequently, boron intake was calculated useing the boron content database of the foods commonly consumed by Romanian urban and rural people. We utilised the analytical B nutrient database that was previously developed for the purpose of estimating B intake.
Primary outcome measure(s) Determination of biochemical parameters. Blood samples for biochemical analyses were taken from fasting venous blood in the morning at the start, and after 2 weeks of treatment. Commercial tubes without anticoagulant were used to collect blood for determination of biochemical parameters. Basic biochemical parameters, lipid profile (total cholesterol, high density lipoprotein [HDL-], low density lipoprotein [LDL-] cholesterol, and inflammatory markers (C-reactive protein [CRP], erythrocyte sedimentation rate [ERS] and fibrinogen) were analysed in serum by standard biochemical procedures using the Hitachi 911 automatic analyser and kits (Roche, Switzerland). Due to known correlations between selected markers, the following ratios were used for processing the data: CHOL/CRP and HDL/CRP.
Secondary outcome measure(s) In neurological literature on diabetic peripheral neuropathy, several neuropathic symptoms and signs scales have been developed, such as the Neurological Symptom Score, the extensive Neuropathy Symptom Profile, and the Neurological Disability Score [B]. These physician-based scales are used primarily in diabetic neuropathy trials in order to diagnose the absence or presence of peripheral neuropathy, although the Neurological Symptom Score does not emphasise actual severity of complaints. Furthermore, consensus guidelines have been published on quantitative sensory testing [B], and on standardised measures in diabetic neuropathy [B]. We used said guidelines to determine paresthesias numbness.

These were measured at the first visit in the day when study begun, and the next measure was done after 2 weeks.
Sources of funding 1. Natural Research, Ltd (Romania) - Research Project (ref: 12/2008)
2. University of Medicine and Pharmacy of Craiova (Romania)
Trial website
Publications
Contact name Prof  Romulus  Scorei
  Address a.i.cuza no.13
  City/town Craiova
  Zip/Postcode 200385
  Country Romania
  Tel +40 (0)251 41 59 60
  Fax +40 (0)251 41 59 60
  Email romulusscorei@gmail.com
Sponsor Natural Research, Ltd (Romania)
  Address a.i.cuza no.13
  City/town Craiova
  Zip/Postcode 200285
  Country Romania
  Tel +40 (0)251 41 59 60
  Fax +40 (0)251 41 59 60
  Email romulus_ion@yahoo.com
  Sponsor website: http://www.naturalresearch.ro/
Date applied 23/02/2010
Last edited 17/03/2010
Date ISRCTN assigned 17/03/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central